长期低剂量罗红霉素联合茶碱缓释片治疗支气管扩张稳定期临床观察

Clinical observation of long term low dose roxithromycin combined with theophylline sustained-release tablets in the treatment of bronchiectasis in stable stage

目的探讨长期低剂量罗红霉素联合茶碱缓释片治疗支气管扩张稳定期的临床疗效及安全性。方法选择2010年9月-2012年3月收治的支气管扩张患者68例,随机分成治疗组和对照组各34例,治疗组给予长期口服低剂量罗红霉素和茶碱缓释片,对照组给予常规对症治疗。观察2组治疗1年内急性发作的次数、1年后呼吸困难指数(mMRC)评分、FEV1/FVC及FEV1%(FEV1与预计值的比)及1年后治疗组治疗前后ALT、AST、DBIL水平。结果治疗组1年内急性发作的次数、1年后mMRC评分及FEV1/FVC及FEV1%均优于对照组,差异均具有统计学意义(P<0.05)。治疗组治疗前后ALT、AST、DBIL比较差异无统计学意义(P>0.05)。结论长期低剂量罗红霉素联合茶碱缓释片治疗支气管扩张稳定期疗效满意且安全性较高。

Objective To explore the clinical effect and safty of long term low dose roxithromycin combined with the- ophylline sustained＇release tablets in the treatment of bronchiectasis in stable stage. Methods 68 cases of patients with bron- chiectasis from September in 2010 to March in 2012 in our hospital were randomly divided into treatment group and control group, each of 34 cases. The treatment group was treated with long term low dose roxithromycin combined with theophylline sus- tained-release tablets, while the control group was received routine treatment. The number of acute attack in 1 year, Dyspnea in- dex （mMRC） score, FEV1/FVC, FEV1%, and ALT,AST,DBIL level of 2 groups were observed. Results The number of a- cute attack in 1 year,Dyspnea index （mMRC） score,FEV1/FVC and FEVI% of the treatment group were better than those of the control group, and the differences were statistically significant （ P 〈 0.05） 5. There was no significant difference of ALT, AST,DBIL level before and after treatment in treatment group （ P 〉 0：05 ）. Conclusion Long term low dose roxithromycin combined with theophylline sustained-release tablets has satisfying effects and higher safety in the treatment of bronchiectasls in stable stage.